Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Supernus Pharmaceuticals (SUPN)
NASDAQ:SUPN
RESEARCH TOOLSreports
Supernus Pharmaceuticals (SUPN) Stock Price & Analysis
469 Followers
SUPN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$21.99 - $35.96
Previous Close$28.74
Volume1.09M
Average Volume (3M)442.31K
Market Cap
$1.58B
Enterprise Value$1.41B
Total Cash (Recent Filing)$200.19M
Total Debt (Recent Filing)$33.84M
Price to Earnings (P/E)-101.1
Beta0.68
Next Earnings
Aug 06, 2024EPS Estimate
$0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding54,974,254
10 Day Avg. Volume542,692
30 Day Avg. Volume442,315
Standard Deviation0.10
R-Squared0.27
Alpha-0.00859
Financial Highlights & Ratios
Price to Book (P/B)10.34
Price to Sales (P/S)2.37
Price to Cash Flow (P/CF)11.10
P/FCF Ratio11.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.32
Enterprise Value/Gross Profit2.44
Enterprise Value/Ebitda12.44
Forecast
1Y Price Target
$40.50Price Target Upside38.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Supernus Pharmaceuticals News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SUPN FAQ
What was Supernus Pharmaceuticals’s price range in the past 12 months?
Supernus Pharmaceuticals lowest stock price was $21.99 and its highest was $35.96 in the past 12 months.
What is Supernus Pharmaceuticals’s market cap?
Currently, no data Available
When is Supernus Pharmaceuticals’s upcoming earnings report date?
Supernus Pharmaceuticals’s upcoming earnings report date is Aug 06, 2024 which is in 81 days.
How were Supernus Pharmaceuticals’s earnings last quarter?
Supernus Pharmaceuticals released its earnings results on May 08, 2024. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.262 by -$0.262.
Is Supernus Pharmaceuticals overvalued?
According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Undervalued.
Does Supernus Pharmaceuticals pay dividends?
Supernus Pharmaceuticals does not currently pay dividends.
What is Supernus Pharmaceuticals’s EPS estimate?
Supernus Pharmaceuticals’s EPS estimate is $0.39.
How many shares outstanding does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals has 54,974,255 shares outstanding.
What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?
Supernus Pharmaceuticals reported an EPS of $0 in its last earnings report, missing expectations of $0.262. Following the earnings report the stock price went down -4.153%.
Which hedge fund is a major shareholder of Supernus Pharmaceuticals?
Among the largest hedge funds holding Supernus Pharmaceuticals’s share is Third Avenue Management LLC. It holds Supernus Pharmaceuticals’s shares valued at 5M.
---
Supernus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.50 (38.89% Upside)
$40.50 (38.89% Upside)
Blogger Sentiment
Bullish
SUPN Sentiment 80%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 18.3K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.27%
12-Months-Change
Fundamentals
Return on Equity
-1.68%
Trailing 12-Months
Asset Growth
-27.22%
Trailing 12-Months
Company Description
Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
---
SUPN Earnings Call
Q1 2024
0:00 / 0:00
---
SUPN Stock 12 Month Forecast
Average Price Target
$40.50
▲(38.89% Upside)
Technical Analysis
Best Analysts Covering SUPN
1 Year
1 Year Success Rate
10/23 ratings generated profit
1 Year Average Return
+2.86%
reiterated a buy rating 8 days ago
Copying David Amsellem's trades and holding each position for 1 Year would result in 43.48% of your transactions generating a profit, with an average return of +2.86% per trade.
---